Home
About
Overview
Sharing Data
ORCID
Help
History (0)
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Salgia, Ravi
One or more keywords matched the following items that are connected to
Salgia, Ravi
Item Type
Name
Academic Article
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Academic Article
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Academic Article
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Academic Article
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Academic Article
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Academic Article
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Academic Article
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Academic Article
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Academic Article
Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.
Academic Article
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
Academic Article
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Academic Article
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Academic Article
Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC).
Concept
Erlotinib Hydrochloride
Search Criteria
Erlotinib Hydrochloride